Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA

Understanding mechanisms of late/acquired cancer immunotherapy resistance is critical to improve outcomes; cellular immunotherapy trials offer a means to probe complex tumor–immune interfaces through defined T cell/antigen interactions. We treated two patients with metastatic Merkel cell carcinoma w...

Descripción completa

Detalles Bibliográficos
Autores principales: Paulson, K. G., Voillet, V., McAfee, M. S., Hunter, D. S., Wagener, F. D., Perdicchio, M., Valente, W. J., Koelle, S. J., Church, C. D., Vandeven, N., Thomas, H., Colunga, A. G., Iyer, J. G., Yee, C., Kulikauskas, R., Koelle, D. M., Pierce, R. H., Bielas, J. H., Greenberg, P. D., Bhatia, S., Gottardo, R., Nghiem, P., Chapuis, A. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155241/
https://www.ncbi.nlm.nih.gov/pubmed/30250229
http://dx.doi.org/10.1038/s41467-018-06300-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155241/
https://www.ncbi.nlm.nih.gov/pubmed/30250229
http://dx.doi.org/10.1038/s41467-018-06300-3

Ejemplares similares